Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

July 22, 2024

Study Completion Date

July 22, 2024

Conditions
Primary Ciliary Dyskinesia
Interventions
DRUG

Albuterol

Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.

DIAGNOSTIC_TEST

Technetium99m - Sulfur Colloid (Tc99m-SC)

Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 microcurie (µCi) deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive three quarters of the adult dose to account for the smaller lung volume.

Trial Locations (1)

27514

University of North Carolina Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of North Carolina, Chapel Hill

OTHER